...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy >A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients.
【24h】

A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients.

机译：儿科患者对大环内酯敏感和大环内酯耐药的肺炎支原体感染的比较临床研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1%) were classified as MS-M. pneumoniae and 30 (31.9%) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5% for MS-M. pneumoniae and 22.7% for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.
机译：近年来，对大环内酯类耐药的肺炎支原体（MR-M。pneumoniae）的患病率增加已成为日本的一个重要问题。我们分离了94株肺炎支原体，并确定了大环内酯类和其他抗菌剂的最低抑制浓度（MIC）。我们还对大环内酯类药物治疗MR-M病例进行了比较临床评估。肺炎支原体感染和大环内酯敏感型肺炎支原体感染（MS-M。pneumoniae）病例。在94株肺炎支原体分离物中，有64株（68.1％）被归类为MS-M。肺炎和30（31.9％）作为MR-M。肺炎菌株。临床研究包括对47例MS-M儿科病例的评估。肺炎和22例MR-M患儿。肺炎在两个研究组之间，患者的性别，年龄，从感染开始到第一次检查的时间，实验室检查结果，诊断和症状的严重程度等人口统计数据均无显着差异。然而，大环内酯治疗MS-M的疗效为91.5％。肺炎和MR-M占22.7％。肺炎的发生率有统计学意义（P <0.01）。尽管一般认为肺炎支原体感染是可以治疗的疾病，但肺炎支原体对大环内酯类耐药菌株的流行率增加已成为小儿患者的重要临床问题，因此有必要仔细考虑针对MR的适当抗菌治疗-M肺炎感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号